CE marking UKCA MHRA recognition 2026 has become one of the most searched regulatory topics for medical device distributors entering the UK market. The MHRA’s targeted consultation on indefinite CE marking recognition closed on 10 April 2026. The outcome matters directly to every manufacturer and distributor placing medical devices on the Great Britain market. For companies currently relying on CE marking to access the UK, the decision determines whether UKCA conformity assessment will eventually become mandatory, and when.
This guide explains what CE marking and UKCA marking are, what the three consultation proposals contained, what the MHRA has decided so far, and what manufacturers and distributors should do to protect their UK market access position.
What CE marking and UKCA marking are
Before addressing the consultation outcome, it helps to be clear on what each mark covers and where it applies.
CE marking is the European conformity mark. It confirms a medical device meets the requirements of the EU Medical Device Regulation (EU MDR 2017/745) or, for legacy devices, the earlier EU Medical Devices Directive (EU MDD 93/42/EEC). CE marking allows a device to be placed on the market across all EU member states. It is issued following conformity assessment by a notified body for Class IIa, IIb, and III devices.
UKCA marking is the UK Conformity Assessed mark. It was created after Brexit as the Great Britain equivalent of CE marking for England, Scotland, and Wales. In principle, UKCA marking requires a separate conformity assessment through a UK-approved body. In practice, mandatory UKCA marking has been repeatedly deferred because the UK-approved body infrastructure was not ready and because approximately 90% of devices on the GB market currently rely on CE marking.
Northern Ireland is different. Under the Windsor Framework, medical devices placed on the Northern Ireland market must comply with EU medical device legislation and be CE-marked. UKCA marking does not apply in Northern Ireland. This distinction is critical for distributors operating across the whole of the UK. Understanding CE marking UKCA MHRA recognition 2026 is therefore essential for any distributor planning UK-wide market coverage.
What the current transitional arrangements mean right now
Under the current framework, CE-marked medical devices are accepted in Great Britain under transitional provisions that vary by device class and the EU legislation under which they were certified.
Devices certified under the EU MDD are accepted in GB until 30 June 2028, aligned with the EU’s own extended transitional deadline for legacy MDD devices. Devices certified under the EU MDR or IVDR are accepted in GB until 30 June 2030. After those deadlines, under the pre-consultation framework, full UKCA conformity assessment was expected to become mandatory.
This means that right now, in 2026, any CE-marked medical device, including video laryngoscope systems certified under EU MDR can be lawfully placed on the Great Britain market. There is no immediate compliance action required solely on the basis of market access marking. The pressure comes from the question of what happens after 2028 and 2030.
What the three MHRA consultation proposals contained
The MHRA consultation, which ran from 16 February to 10 April 2026, contained three distinct proposals for stakeholder feedback.
Proposal 1: Six-month extension of MDD transitional arrangements. This proposal would extend the current GB transitional arrangements for EU MDD-compliant devices from 30 June 2028 to 31 December 2028, aligning them with the EU MDR transition timeline. This is a technical alignment measure rather than a fundamental policy change.
Proposal 2: Indefinite recognition of CE-marked EU MDR and IVDR devices. This is the proposal that attracted most industry attention. It would provide permanent recognition in GB for CE-marked devices compliant with the EU MDR or the EU IVDR. Under this proposal, manufacturers would not need to obtain separate UKCA marking for EU MDR-certified devices. EU conformity assessment decisions would effectively determine access to the GB market without additional UK approved body review.
Proposal 3: International reliance route. This proposal would create a new pathway where the MHRA gives significant weight to EU MDR and IVDR conformity assessments but still conducts its own review and retains final market-access responsibility. Devices completing this process would receive a certificate of international reliance, valid for the same period as the relevant EU certificate. Importantly, this route would not be available for devices relying on EU self-declaration that fall into a higher GB risk class.
Industry reaction to Proposal 2 was overwhelmingly positive. MHRA Chief Executive Lawrence Tallon explicitly stated that long-term recognition of the CE mark was the “number one request” from the medical device industry, and that the proposed reforms were strategically aimed at supporting supply chain resilience and ensuring continuous patient access.
What the MHRA actually decided
This is the critical finding for any distributor or manufacturer reading this post. The consultation outcome has been published.
In response to recurring requests to indefinitely extend the recognition of CE-marked medical devices, the MHRA confirmed that the proposed routes for CE-marked devices will not be implemented at this time. The recognition of CE-marked devices will not be included in the new pre-market legislation anticipated to be released later in 2026. However, under the current transitional arrangements, CE-marked devices will continue to be accepted in GB until June 2028 or June 2030, depending on the specific device.
In plain terms, indefinite CE recognition was not granted. The MHRA deferred the decision to a further consultation round rather than implementing it in the forthcoming pre-market legislation. CE-marked devices remain valid in GB under the existing transitional timelines, but the long-term question of whether UKCA marking will eventually become mandatory has not been resolved.
As Distilled Post’s regulatory summary confirms, the MHRA committed to a thorough review of all submitted consultation responses, with the final framework anticipated to be implemented later in 2026. This means the regulatory picture for 2028 and beyond will become clearer in the second half of 2026 when the MHRA publishes its pre-market legislation and any further CE recognition decision.
What this outcome means for manufacturers and distributors
The practical implications depend on where a company sits in the supply chain and when their current CE certificates expire.
For manufacturers with EU MDR certificates valid through 2028 or 2030:
No immediate action is required for GB market access. CE-marked devices remain lawfully placeable on the GB market under the current transitional arrangements. However, planning for the post-2028 and post-2030 landscape should begin now, because the MHRA has not committed to indefinite recognition and UKCA conformity assessment may ultimately be required.
For manufacturers with EU MDD certificates expiring before 2028:
Begin the transition to EU MDR conformity assessment as a priority. EU MDR certification resolves both the EU and GB market access question simultaneously and provides the strongest foundation for whatever the MHRA decides in its forthcoming pre-market legislation.
For distributors evaluating a manufacturer’s UK market readiness:
Confirm the manufacturer holds a current CE certificate under EU MDR or EU MDD with a validity date that extends to at least June 2028. Certificates expiring before that date require renewal through an EU notified body or UK approved body before the device can continue to be placed on the GB market.
For distributors operating across GB and Northern Ireland:
Remember that Northern Ireland operates under different rules. CE-marked devices are required for the Northern Ireland market regardless of the GB framework. Distributors selling across the whole of the UK need a CE-marked device in all scenarios.
The UKCA marking question: what it means in practice
Despite repeated deferrals, UKCA marking has not been abolished. It remains the long-term regulatory direction for GB market access for manufacturers who do not qualify under whatever CE recognition framework the MHRA ultimately implements.
As Jones Day’s analysis notes, in practice, self-declared Class I devices that would be classified as Class IIa in GB, and self-declared Class A IVDs that fall into a higher GB risk class, would not qualify for the international reliance route and therefore must undergo UKCA conformity assessment to access the GB market.
Video laryngoscopes are Class IIa devices in both the EU and GB frameworks. Under Proposal 3’s international reliance route, they would have qualified for the reliance pathway. Under the current outcome, which defers both proposals 2 and 3, they remain subject to the existing transitional arrangements until the MHRA publishes further legislation.
For manufacturers planning a GB market entry or a long-term UK distribution strategy, the safest approach is to pursue EU MDR certification as the primary conformity route. EU MDR certification covers both EU market access and GB transitional market access simultaneously, and positions the manufacturer for whatever the MHRA’s final CE recognition decision turns out to be.
What the MHRA’s broader reform programme means for 2026 and 2027
The CE recognition consultation sits within a wider MHRA regulatory reform programme. New pre-market legislation amending the UK Medical Devices Regulations 2002 is anticipated later in 2026. This legislation will define the long-term framework for GB market access.
The Pure Clinical regulatory overview confirms that the MHRA has been clear that its reform objectives are a risk-proportionate, pro-innovation, patient-focused regime that supports the UK’s goal of becoming a leading country for medtech access by 2030. The CE recognition question will be addressed within that broader legislative context.
For distributors and manufacturers, the practical implication is to monitor MHRA publications closely in the second half of 2026. The pre-market legislation announcement will be the most significant UK regulatory event for medical devices since Brexit and will determine whether UKCA conformity assessment eventually becomes mandatory or whether CE recognition is formalised on a permanent basis.
For a full breakdown of the MHRA’s 2026 registration fee changes and the operational obligations that apply right now regardless of the CE recognition outcome, see our guide on MHRA registration for medical devices in 2026.
What manufacturers and distributors should do right now
Based on the current regulatory position, the following steps represent the practical priority list for any company with UK market interests.
Step 1: Confirm your CE certificate validity date. Check whether your current CE certificate is valid under EU MDR or EU MDD, and when it expires. EU MDR certificates are valid in GB until June 2030 under current transitional arrangements. EU MDD certificates are valid until June 2028.
Step 2: Plan your EU MDR transition if still on EU MDD. EU MDD transitional arrangements end in 2028. Beginning the EU MDR conformity assessment process now avoids a compliance gap and simultaneously protects GB market access.
Step 3: Appoint or confirm your UKRP. A UK Responsible Person remains required for non-UK manufacturers placing devices on the GB market, regardless of the CE recognition outcome. Confirm your UKRP appointment is current and their DORS registration is active.
Step 4: Monitor MHRA pre-market legislation in H2 2026. The forthcoming legislation will define the long-term CE recognition position. Subscribe to MHRA regulatory updates and factor the legislative timeline into your UK market planning.
Step 5: Do not assume indefinite CE recognition is confirmed. The MHRA deferred the decision. Planning on the basis that UKCA marking will never be required is a strategic risk. Build UKCA as a contingency scenario in your UK regulatory strategy.
Astra-vue’s video laryngoscope systems are CE-marked under EU MDR, providing valid GB market access under the current transitional arrangements through June 2030. For information on UK distributor arrangements, regulatory documentation, and market support, contact our team or explore the full product line.
Frequently asked questions about CE marking, UKCA, and MHRA recognition in 2026
Can CE-marked medical devices still be sold in Great Britain in 2026?
Yes. Under the current transitional arrangements, CE-marked devices compliant with EU MDR or IVDR are accepted in GB until June 2030. CE-marked devices compliant with EU MDD are accepted until June 2028. The MHRA consultation closed in April 2026 without implementing indefinite recognition, but the existing transitional timelines remain in force.
Did the MHRA grant indefinite CE recognition after the April 2026 consultation?
No. The MHRA confirmed that the proposed routes for CE-marked devices will not be implemented at this time and will not be included in the new pre-market legislation anticipated later in 2026. CE-marked devices continue to be accepted under existing transitional arrangements. The MHRA committed to further consultation as part of its broader reform programme.
Is UKCA marking currently required for medical devices in Great Britain?
Not yet for most devices. Under transitional arrangements, CE-marked devices continue to be accepted in GB. UKCA marking has been repeatedly deferred and its mandatory implementation date has not been confirmed. However, it has not been abolished. The MHRA’s forthcoming pre-market legislation will provide greater clarity on whether UKCA will ultimately become mandatory.
Does CE marking apply in Northern Ireland?
Yes. Under the Windsor Framework, medical devices placed on the Northern Ireland market must comply with EU medical device legislation and carry CE marking. UKCA marking does not apply in Northern Ireland. This distinction is important for distributors selling across the whole of the UK.
What is the safest regulatory strategy for a manufacturer entering the GB market?
Pursue EU MDR conformity assessment as the primary route. EU MDR certification covers both EU and GB market access under current transitional arrangements and positions the manufacturer for the best outcome regardless of whether the MHRA ultimately grants indefinite CE recognition or requires UKCA conformity assessment.
